TBCRC 018: Phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases

Breast Cancer Research and Treatment

Volumn 146, Issue 3, 2014, Pages 557-566

  Anders, Carey ^a,p   Deal, Allison M ^a   Abramson, Vandana ^b   Liu, Minetta C ^c   Storniolo, Anna M ^d   Carpenter, John T ^e   Puhalla, Shannon ^f   Nanda, Rita ^g   Melhem Bertrandt, Amal ^h   Lin, Nancy U ⁱ   Kelly Marcom, P ^j   Van Poznak, Catherine ^k   Stearns, Vered ^l   Melisko, Michelle ^m   Smith, J Keith ^a   Karginova, Olga ^a   Parker, Joel ^a   Berg, Jonathan ^a   Winer, Eric P ⁱ   Peterman, Amy ⁿ   Prat, Aleix ^o   Perou, Charles M ^a   Wolff, Antonio C ^l   Carey, Lisa A ^a,p   more..

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

^j DUKE UNIVERSITY   (United States)

^k UNIVERSITY OF MICHIGAN   (United States)

^l JOHNS HOPKINS UNIVERSITY   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE   (United States)

^o VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^p UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

more..

Author keywords

Brain metastases; Breast cancer; Iniparib; Irinotecan; Phase II; Triple negative

Indexed keywords

INIPARIB; IRINOTECAN; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; CAMPTOTHECIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONSTIPATION; DEHYDRATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL DISEASE; GENE EXPRESSION; GERMLINE MUTATION; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; LYMPHATIC SYSTEM DISEASE; MULTICENTER STUDY; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL TIME; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE; VOMITING; ADVERSE DRUG REACTION; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; BRAIN NEOPLASMS; CANCER STAGING; CLINICAL TRIAL; FEMALE; GENETICS; MIDDLE AGED; PATHOLOGY; SECONDARY; SURVIVAL; TRIPLE NEGATIVE BREAST NEOPLASMS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAMIDES; BRAIN NEOPLASMS; CAMPTOTHECIN; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS; TRIPLE NEGATIVE BREAST NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84907598545     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3039-y     Document Type: Article

References (34)

1. Lin NU et al (2008) Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer. Cancer 113(10):2638-2645
2. Niwińska A, Murawska M, Pogoda K (2010) Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol 21(5):942-948
3. Niwińska A, Murawska M, Pogoda K (2010) Breast cancer subtypes and response to systemic treatment afterwhole-brain radiotherapy in patients with brain metastases. Cancer 116(18):4238-4247
4. Licht S, et al. (2011) Mechanism of action of iniparib: stimulation of reactive oxygen species (ROS) production in an iniparib-sensitive breast cancer cell line. Mol Cancer Ther 10(11 Suppl: Abstract A226)
5. Castro M, Li L, Stallings T (2010) Pharmacokinetics of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in cerebrospinal fluid (CSF) of a patient with breast cancer with carcinomatous meningitis. J Clin Oncol (Meet Abstr) 28:e13559
6. O'Shaughnessy J et al (2011) A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 29(S):1007
7. Perez EA et al (2004) Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol 22(14):2849-2855 (Pubitemid 41079903)
8. O'Shaughnessy J, et al. (2007) Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. Breast Cancer Res Treat 106(Suppl 1 Abstract 308)
9. BiPar (2011) BSI-201 Investigator's Brochure
10. Vredenburgh JJ et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30):4722-4729 (Pubitemid 350086473)
11. Moulder S, et al. (2010) A phase 1b study to assess the safety and tolerability of iniparib (BSI-201) in combination with irinotecan for the treatment of metastatic breast cancer. In: San Antonio breast cancer symposium. 2010
12. Blakeley J et al (2010) Poly (ADP-ribose) polymerase-1 (PARP1) inhibitor BSI-201 in combination with temozolomide (TMZ) in malignant glioma. J Clin Oncol 28(15S):2012A
13. Lin NU et al (2008) Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 26(12):1993-1999
14. Lin NU et al (2009) Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15(4):1452-1459
15. Eisenhauer E et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228-247
16. Geiss GK et al (2008) Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 26(3):317-325 (Pubitemid 351355126)
17. Parker JS et al (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27(8):1160-1167
18. Prat A et al (2010) Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12(5):R68
19. Nielsen TO et al (2010) A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 16(21):5222-5232
20. Hu Z et al (2009) A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med 7(1):9
21. Brady MJ et al (1997) Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument. J Clin Oncol 15(3):974-986 (Pubitemid 27106280)
22. Weitzner MA et al (1995) The functional assessment of cancer therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 75(5):1151-1161
23. Cella DF et al (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11(3):570-579 (Pubitemid 23071057)
24. Epstein B (1960) Statistical life test acceptance procedures. Technometrics 2.4(4):435-446
25. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci 98(9):5116-5121 (Pubitemid 32397092)
26. Huang DW, Sherman BT, Lempicki RA (2008) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4(1):44-57
27. Gaspar LE et al (2000) Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys 47(4):1001-1006 (Pubitemid 30345599)
28. Prat A et al (2013) Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist 18(2):123-133
29. Carey LA et al (2012) TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol 30(21):2615-2623
30. Baselga J, et al. (2013) Randomized phase II study of the antiepidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol 31(20):2586-2592
31. Lin N, Gelman R, Younger W et al (2013) Phase II trial of carboplatin (C) and bevacizumab (BEV) in patients (pts) with breast cancer brain metastases (BCBM). J Clin Oncol 31 (suppl; abstr 513)
32. O'Shaughnessy J et al (2011) Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 364(3):205-214
33. Prat A, et al. (2012) Gene expression-based predictors of chemotherapy response in basal-like breast cancer. J Clin Oncol 30 (suppl; abstr 10500)
34. Lin NU et al (2013) Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet 14(10):e407-e416